Neuropsychopharmacologic treatment of depression and other neuropsychiatric disorders in HIV-infected individuals.
How can neuropsychiatric disorders and syndromes be underdiagnosed and inadequately treated in individuals infected with human immunodeficiency virus? Depression in particular is among the most prevalent diagnoses and there is a solid foundation of data from controlled clinical studies that has begun to examine the efficacy of various antidepressants in HIV-infected persons. This article summarizes essential findings pertaining to the use of psychotropic medications to treat depression and other neuropsychiatric disorders in the context of immunodeficiency. This includes discussion of clinically significant treatment considerations (eg, efficacy, side effects, drug-drug interactions) derived from the existing literature. Taken together, there is compelling evidence that psychopharmacologic intervention can improve the quality of life of mentally ill HIV-infected individuals.
Repetto
Martin J
MJ
McKnight Brain Institute, Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL 32610-0256, USA.
Evans
Dwight L
DL
Cruess
Dean G
DG
Gettes
David R
DR
Douglas
Steven D
SD
Petitto
John M
JM
D015526:AIDS Dementia Complex / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D015658:HIV Infections / Q000188:drug therapy / Q000523:psychology*; D006801:Humans; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000928:Antidepressive Agents; D011619:Psychotropic Drugs